The Top 5 Biosimilars Articles for the Week of July 23

Transcript:

Hi, I’m Samantha DiGrande for The Center for Biosimilars^®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of July 23.

Number 5: Six months after patients switched from reference infliximab to biosimilar infliximab, there was no meaningful increase in patients’ outpatient healthcare use, according to a new study.

Number 4: The Biosimilars Competition Act of 2018 has been introduced in the United States House of Representatives. The bill would require biologic and biosimilar drug manufacturers to report any agreements they enter into that may keep lower-cost drugs from reaching consumers.

Number 3: A little over a year after having received FDA authorization for its clinical program, Glenmark Pharmaceuticals has announced positive phase 1 data from a trial of its Xolair biosimilar.

Number 2: In an interview with The Center for Biosimilars^®, executives from Pfizer discussed the state of the US biosimilars marketplace.

Number 1: In order to gather stakeholder input on the initiatives explained in the Biosimilar Action Plan unveiled by FDA Commissioner Scott Gottlieb, MD, last week, the FDA has announced that it will hold a public hearing on the plan in September.

Finally, last week, our e-newsletter asked whether the price point for Mylan’s pegfilgrastim biosimilar is low enough to spark uptake.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.